Screener / SEC EDGAR /CIK 0001635088 /10-K filed May 20, 2026, compared with May 29, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Roivant Sciences Ltd. ROIV

Compare with peers Embed
In the footnotes

What the 10-K filed May 20, 2026 says off the balance sheet

10-K notes
Topics with specifics 3 of 6 with a sentence that gives amounts, accruals or ratios
Sentences quoted 10 word for word, each linked to the 10-K
New this year 7 sentences with nothing like them in the 10-K filed May 29, 2025

Risks that are not on the face of the balance sheet. Tickdelta picks sentences with specifics and quotes them as filed. New marks a sentence with nothing like it in the 10-K filed May 29, 2025.

Big customers

Customers the company names as a large share of revenue or receivables (it must name any worth 10% of revenue).

No specific sentence about this in the 10-K.

Key suppliers

Parts or manufacturing that depend on one or a few suppliers.

1 new

New “reliance on a limited number of sources, and in some cases, single sources for product components, such that if we are unable to secure a sufficient supply of these product components, we will be unable to manufacture and sell our product candidates following regulatory approval in a timely fashion, in sufficient quantities or under acceptable terms;”

Read it in the 10-K

“lack of qualified backup suppliers for those components that are currently purchased from a sole or single source supplier;”

Read it in the 10-K

“We may be dependent on one or a limited number of suppliers for certain components of our product candidates.”

Read it in the 10-K

Lawsuits and legal claims

Pending cases, settlements and what the company has set aside for them.

5 new

New “Gain on litigation settlement reflects a gain resulting from the settlement agreement (the “Settlement Agreement”) entered between our subsidiary, Genevant Sciences GmbH (“Genevant”), Arbutus Biopharma Corporation (together with Genevant, “Genevant/Arbutus”), and, solely for certain purposes, Genevant’s parent Genevant Sciences Ltd., and Moderna, Inc. and ModernaTx, Inc.”

Read it in the 10-K

New “We recognized a gain on litigation settlement of $770.2 million during the year ended March 31, 2026 in the accompanying consolidated statements of operations for Genevant’s expected portion of the $950 million non-contingent, non-creditable, and non-refundable payment to be made by Moderna to Genevant and Arbutus on or before July 8, 2026 (the “Fixed Payment”).”

Read it in the 10-K

New “This increase was primarily due to an increase in share-based compensation expense of $58.8 million, primarily due to the long-term equity incentive awards from the Senior Executive Compensation Program and incremental share-based compensation expense resulting from the Priovant Exchange Offer, an impairment loss of $17.1 million related to the relocation of the U.S. corporate headquarters of Roivant Sciences, Inc. and an increase of $9.1 million in professional fees, reflecting higher litigation-related costs incurred.”

Read it in the 10-K

New “Gain on litigation settlement $ 770,235 $ $ $ 770,235 $”

Read it in the 10-K

New “The Company accordingly recognized a gain on litigation settlement of $770.2 million during the year ended March 31, 2026 in the accompanying consolidated statements of operations and a corresponding litigation settlement receivable of $770.2 million on the accompanying consolidated balance sheets.”

Read it in the 10-K

Guarantees and indemnities

Promises to pay someone else's debts or losses if they cannot.

1 new

“The aggregate maximum potential future liability of the Company under such indemnification provisions is uncertain.”

Read it in the 10-K

New “The maximum amount of potential future indemnification is unlimited; however, the Company currently maintains director and officer liability insurance, which may cover certain liabilities arising from the Company’s obligation to indemnify its directors and officers.”

Read it in the 10-K

Debt covenants

Conditions in loan agreements that, if broken, can make debt due early.

No specific sentence about this in the 10-K.

Commitments off the balance sheet

Contracts the company must pay for later: purchase obligations, take-or-pay deals.

No specific sentence about this in the 10-K.

Customers it names 0 tracked companies its filings call a customer
Suppliers it names 0 tracked companies its filings call a supplier
Companies that name it 0 tracked companies whose filings call it a customer or a supplier

Companies it names

Tracked companies that its latest 10-K or its 8-Ks of the last year call a customer or a supplier.

No other tracked company is named as a customer or a supplier in the latest filings.

Companies that name it

Tracked companies whose latest 10-K or 8-Ks call it a customer or a supplier.

No other tracked company names it as a customer or a supplier in the latest filings.

Sentences are chosen by their words, not read by AI, so some can be off topic. Always check the filing. Open the 10-K

Sources

The notes to the financial statements, Legal Proceedings and the MD&A of the latest 10-K (and, for customers and suppliers, Business and Risk Factors), quoted as filed.

Also

Debt: the debt note in numbers.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ROIV/export.csv") into a cell.

Next:Reverse DCF
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.